| Dr Vladimir Zuzukin, MD | |
|
8030 Crowder Blvd, Suite B, New Orleans, LA 70127-1072 | |
| (214) 934-0200 | |
| (504) 324-2336 |
| Full Name | Dr Vladimir Zuzukin |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | 8030 Crowder Blvd, New Orleans, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588839153 | NPI | - | NPPES |
| 1480886 | Medicaid | LA |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vladimir Zuzukin, MD 8030 Crowder Blvd, Suite B, New Orleans, LA 70127-1072 Ph: (214) 934-0200 | Dr Vladimir Zuzukin, MD 8030 Crowder Blvd, Suite B, New Orleans, LA 70127-1072 Ph: (214) 934-0200 |
News Archive
Eleven big food companies, including McDonald's, Pepsi Co. and General Mills, have all agreed to stop advertising products to children under 12 that do not meet certain nutritional requirements.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.
Penwest Pharmaceuticals Co. today announced that it has signed a drug development and commercialization agreement with Alvogen, Inc. under which Penwest and Alvogen have agreed to identify and select up to five compounds for generic development. Penwest's TIMERx technology may be used for each compound selected.
PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that the companies have achieved a milestone in the development of their in vivo glucose-sensing RFID microchip to detect glucose levels in the body. The companies have completed the synthesis of a new chemical building block that will serve as the anchor of their next generation of Combinatorial Artificial Receptor (CARA™) surfaces for the sensing system component of the implantable glucose sensor.
› Verified 8 days ago
Dr. Parker Anthony Velargo, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2633 Napoleon Ave, Ste: 920, New Orleans, LA 70115 Phone: 504-533-8848 | |
Dr. Timothy B Molony, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Dr. Ray J Lousteau, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 120 N Jefferson Davis Pkwy, New Orleans, LA 70119 Phone: 504-821-0244 Fax: 504-821-0255 | |
Elizabeth Gardner De Laureal, Otolaryngology Medicare: Medicare Enrolled Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Paul Louis Friedlander, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1415 Tulane Ave, Hc-76, New Orleans, LA 70112 Phone: 504-988-5451 Fax: 504-988-1694 | |
Dr. Elisabeth H Rareshide, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2820 Napoleon Ave, Suite 820, New Orleans, LA 70115 Phone: 504-895-7707 Fax: 504-895-7994 | |
Laura Pelaez, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 533 Bolivar St, Ste 566, New Orleans, LA 70112 Phone: 504-568-4785 Fax: 505-568-4460 |